

Date: 22/03/2022

FREEDOM OF INFORMATION REQUEST - Ref: FOI/016084 – Breast cancer

Q1) Between 01/12/2021 and 28/02/2022, the following number of breast cancer patients were issued with the following drugs

We cannot say categorically that the drug was used to treat breast cancer, only that the breast cancer patients were issued with that drug

Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent - 47  
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - 5  
Abemaciclib + Fulvestrant - 0  
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent - 35  
Atezolizumab + Nab-paclitaxel/Paclitaxel - 0  
Capecitabine as a single agent - 8  
Carboplatin or Cisplatin as a single agent - 13  
Eribulin as a single agent or in combination - 1  
Everolimus + Exemestane - 0  
Fulvestrant as a single agent - 1  
Lapatinib - 0  
Neratinib - 0  
Parp Inhibitors (Olaparib/Talazoparib) - 0  
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - 9  
Palbociclib + Fulvestrant - 1  
Pembrolizumab - 1  
Pertuzumab + Trastuzumab + Docetaxel - 18  
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) - 0  
Ribociclib + Fulvestrant - 0  
Sacituzumab Govitecan - 0  
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - 36  
Trastuzumab as a single agent or in combination - 27  
Trastuzumab emtansine - 3  
Trastuzumab deruxtecan - 0  
Vinorelbine as a single agent - 0

Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIc) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, letrozole) as a single agent? - 0